Blog
RSS FeedPosted by Michael Wonder on 01 Jun 2016
NICE to research patient preferences in HTA
1 June 2016 - Myeloma UK has awarded a health services research grant to NICE, to fund an exploratory study on ...
Posted by Michael Wonder on 01 Jun 2016
The challenge of costly drugs
2 June 2016 - From June 2005 to June 2014 the annual cost of the PBS rose from $6 billion to ...
Posted by Michael Wonder on 01 Jun 2016
Ramucirumab in colorectal and lung cancer: some additional benefits, some reductions in benefits
1 June 2016 - Germany's IQWiG has just completed its assessment of Lilly's Cyramza for patients with colorectal cancer or ...
Posted by Michael Wonder on 01 Jun 2016
NICE asks company to put leukaemia drug forward for new Cancer Drugs Fund
1 June 2016 - NICE has published a second appraisal consultation document for ibrutinib for chronic lymphocytic leukaemia. ...
Posted by Michael Wonder on 01 Jun 2016
PBS palliative care schedule
1 June 2016 - As part of the post-market review of Authority Required PBS listings, the restrictions for a number of ...
Posted by Michael Wonder on 31 May 2016
Schedule of Pharmaceutical Benefits - 1 June 2016 update
1 June 2016 - The June 2016 issue of the Schedule is out and now in effect. ...
Posted by Michael Wonder on 31 May 2016
New Zealand Pharmaceutical Schedule - 1 June 2016 update
1 June 2016 - The June 2016 update to the New Zealand Pharmaceutical Schedule sees the listing of one new medicine. ...
Posted by Michael Wonder on 30 May 2016
Proposals to widen funding access to important vaccines
30 May 2016 - PHARMAC is asking the public for feedback on proposals to widen funding access to the varicella (chickenpox) ...
Posted by Michael Wonder on 26 May 2016
CADTH Common Drug Review and pan-Canadian Oncology Drug Review engagement with the pan-Canadian Pharmaceutical Alliance
26 May 2016 - CADTH is engaging with the pan-Canadian Pharmaceutical Alliance office (pCPA), and effective immediately will be including the ...
Posted by Michael Wonder on 26 May 2016
New Zealand budget 2016: extra $2.2 billion pumped into health
26 May 2016 - An extra $2.2 billion will be pumped into health over four years to help cope with an ...
Posted by Michael Wonder on 26 May 2016
NICE issues draft guidance for necitumumab (Portrazza)
26 May 2016 - NICE has released an appraisal consulation document for necitumumab for untreated advanced or metastatic, squamous non-small-cell ...
Posted by Michael Wonder on 25 May 2016
NICE updates guidance on the use of cabazitaxel in patients with hormone-relapsed metastatic prostate cancer treated with docetaxel
24 May 2016 - This guidance replaces NICE technology appraisal guidance on the use of cabazitaxel in patients with hormone-refractory metastatic ...
Posted by Michael Wonder on 25 May 2016
NICE recommends three diabetes treatments
24 May 2016 - The three drugs can all be used on their own if a person can’t use metformin or ...
Posted by Michael Wonder on 23 May 2016
Major parties clash over health
22 May 2016 - Coalition and Labor trade blows over PBS. ...
Posted by Michael Wonder on 23 May 2016
Proposal to award sole supply of bortezomib in DHB hospitals
As Velcade is currently the only funded brand of bortezomib, there would be no funded brand change resulting from this ...